<DOC>
	<DOCNO>NCT00095966</DOCNO>
	<brief_summary>Sorafenib may stop growth tumor cell stop blood flow tumor block enzyme necessary growth . Drugs use chemotherapy , gemcitabine , work different way stop tumor cell divide stop grow die . Giving sorafenib gemcitabine may kill tumor cell . This phase II trial study well give sorafenib together gemcitabine work treat patient locally advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>Sorafenib Gemcitabine Treating Patients With Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine objective response rate patient locally advance metastatic adenocarcinoma pancreas treat sorafenib gemcitabine . II . Determine toxicity experience patient advanced pancreatic cancer treat sorafenib plus gemcitabine . OUTLINE : This multicenter study . Patients receive oral sorafenib twice daily day 1-28 gemcitabine IV 30 minute day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 12-35 patient accrue study within 7 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma pancreas Locally advance metastatic disease Locally advance disease must extend outside boundary standard radiotherapy port Not amenable curative surgery radiotherapy Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Pleural effusion ascites consider measurable lesion Outside prior radiotherapy port No known brain metastasis Performance status ECOG 01 Performance status Karnofsky 70100 % More 3 month WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 No evidence bleed diathesis Bilirubin normal AST and/or ALT ≤ 2.5 time upper limit normal Creatinine normal Creatinine clearance ≥ 60 mL/min No uncontrolled hypertension No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active ongoing infection No active malignancy No history allergic reaction attribute compound similar chemical biological composition sorafenib study agents No psychiatric illness social situation would preclude study compliance No uncontrolled illness No prior antiangiogenic agent No prior cytotoxic chemotherapy metastatic disease At least 4 week since prior adjuvant chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior gemcitabine See Disease Characteristics At least 4 week since prior radiotherapy recover No prior investigational drug No prior sorafenib No prior MAPK signal agent Concurrent warfarin anticoagulation allow provide follow criterion meet : Therapeutic stable warfarin dose INR ≤ 3 Undergo weekly INR test No active bleed pathological condition carry high risk bleed No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>